Yu 2002.

Methods	8‐week dietary and washout run‐in period 8‐week before‐and‐after study
Participants	21 men and women with primary hypercholesterolaemia age 18‐75 years old LDL‐C > 160 mg/dL (4.14 mmol/L), TG < 350 mg/dL (3.95 mmol/L) Exclusion criteria: severe uncontrolled hypertension. diabetes mellitus, uncontrolled hypothyroidism, renal impairment (SCr > 2.0 mg/dL), known chronic liver disease or elevated serum transaminase levels (ALT/AST > 1.5 x ULN). MI, unstable angina, cerebral vascular accident, and TIA within 3 months before the trial; and CABG or PCTA within 6 months before the trial, concomitant treatment with corticosteroids, androgens, erythromycin, oral anticoagulants, or other lipid‐lowering agents was not permitted during the trial. Cerivastatin 0.3 mg/d baseline TC: 6.60 mmol/L (255.2 mg/dL) Cerivastatin 0.3 mg/d baseline LDL‐C: 4.63 mmol/L (179.1 mg/dL) Cerivastatin 0.3 mg/d baseline HDL‐C: 1.31 mmol/L (50.7 mg/dL) Cerivastatin 0.3 mg/d baseline TG: 1.43 mmol/L (126.5 mg/dL)
Interventions	Cerivastatin 0.3 mg/d evening dosing Lovastatin 20 mg/d evening dosing
Outcomes	Percentage change from baseline at 8 weeks of plasma TC, LDL‐C, HDL‐C and TG
Source of funding	Bayer Taiwan Co
Notes	Lovastatin 20 mg/d group was not analysed SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before‐and‐after design
Allocation concealment (selection bias)	High risk	Controlled before‐and‐after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐C	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAE	High risk	No comparison possible
Incomplete outcome data (attrition bias) Total cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) LDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) HDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) Triglycerides	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	High risk	Trial supported by Bayer Taiwan Co. data may support bias for cerivastatin

ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; BP: blood pressure; CABG: coronary artery bypass graft; CAD: coronary artery disease; CK: creatine kinase; CVD: cardiovascular disease; FH: familial hypercholesterolaemia; GI: gastrointestinal; HBA1c: haemoglobin A1c; HDL‐C: high‐density lipoprotein cholesterol; HMG CoA; 3‐hydroxy‐3‐methyl‐glutarylcoenzyme A; HRT: hormone‐replacement therapy; IUD: intrauterine device; LDL‐C: low‐density lipoprotein cholesterol; MI: myocardial infarction; NYHA: New York Heart Association; OCP: oral contraceptive pill; PCI: percutaneous coronary intervention; PTCA: percutaneous transluminal coronary angioplasty; PVD: peripheral vascular disease; RCT: randomised, double‐blind, placebo‐controlled trial; SCr: serum creatinine; SD: standard deviation; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase; SLE: systemic lupus erythematosus; TC: total cholesterol; TG: triglyceride; TIA: transient ischaemic attack; TSH: thyroid‐stimulating hormone; ULN: upper limit of normal; WDAEs: withdrawals due to adverse effects; WHO: World Health Organization